AP3116A - Polynucleotides and polypeptides involved in gestational malaria, and biological applications - Google Patents

Polynucleotides and polypeptides involved in gestational malaria, and biological applications

Info

Publication number
AP3116A
AP3116A AP2009005041A AP2009005041A AP3116A AP 3116 A AP3116 A AP 3116A AP 2009005041 A AP2009005041 A AP 2009005041A AP 2009005041 A AP2009005041 A AP 2009005041A AP 3116 A AP3116 A AP 3116A
Authority
AP
ARIPO
Prior art keywords
polynucleotides
biological applications
polypeptides involved
gestational malaria
gestational
Prior art date
Application number
AP2009005041A
Other languages
English (en)
Other versions
AP2009005041A0 (en
Inventor
Phillippe Lucien Deloron
Peter David
Emmanuel Bischoff
Original Assignee
Pasteur Institut
Inst Rech Developpement Ird
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Rech Developpement Ird filed Critical Pasteur Institut
Publication of AP2009005041A0 publication Critical patent/AP2009005041A0/en
Application granted granted Critical
Publication of AP3116A publication Critical patent/AP3116A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AP2009005041A 2007-04-17 2008-04-17 Polynucleotides and polypeptides involved in gestational malaria, and biological applications AP3116A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702772A FR2915207B1 (fr) 2007-04-17 2007-04-17 Polynucleotides et polypeptides impliques dans le paludisme gestationnel, et applications biologiques.
PCT/IB2008/051482 WO2008126065A2 (fr) 2007-04-17 2008-04-17 Polynucléotides et polypeptides impliqués dans le paludisme gestationnel, et applications biologiques

Publications (2)

Publication Number Publication Date
AP2009005041A0 AP2009005041A0 (en) 2009-12-31
AP3116A true AP3116A (en) 2015-02-28

Family

ID=38613117

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009005041A AP3116A (en) 2007-04-17 2008-04-17 Polynucleotides and polypeptides involved in gestational malaria, and biological applications

Country Status (5)

Country Link
US (1) US8563008B2 (de)
EP (1) EP2145003A2 (de)
AP (1) AP3116A (de)
FR (1) FR2915207B1 (de)
WO (1) WO2008126065A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201318084D0 (en) * 2013-10-11 2013-11-27 Isis Innovation Malaria vaccination
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124712A2 (en) * 2005-05-16 2006-11-23 Merck & Co., Inc. A method for improving the immunogenicity of plasmodium antigens
US20070036819A1 (en) * 2005-08-09 2007-02-15 Michal Fried Malaria vaccines

Also Published As

Publication number Publication date
FR2915207A1 (fr) 2008-10-24
WO2008126065A2 (fr) 2008-10-23
WO2008126065A3 (fr) 2008-12-31
US8563008B2 (en) 2013-10-22
US20100255018A1 (en) 2010-10-07
EP2145003A2 (de) 2010-01-20
FR2915207B1 (fr) 2012-10-05
AP2009005041A0 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
EP2076604A4 (de) Glp-2-mimetikörper, polypeptide, zusammensetzungen, verfahren und verwendungen
EP2046988A4 (de) Echtzeit-pcr in mikrokanälen
EP2115653A4 (de) Dateienkonvertierung in einem eingeschränkten verfahren
IL237314A (en) Insulin polypeptides are modified and their uses
EP2330488A4 (de) Planares element und berührungsschalter
ZA200810323B (en) Fkbp-l and uses thereof
PL2099826T3 (pl) Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
GB2446299B (en) Secure barcode
PL2064327T3 (pl) Dbait i ich zastosowania
IL194751A0 (en) Drugs and uses
GB0708376D0 (en) Novel polypeptides and uses thereof
GB0700914D0 (en) Polynucleotides and uses thereof
GB0823309D0 (en) Functionalising reagents and their uses
ZA200903906B (en) Carboranylporphyrins and uses thereof
DK1934383T5 (da) Strømløs plettering i mikrokanaler
GB0701062D0 (en) Biological materials and uses thereof
EP2146583A4 (de) Glykosylierte milch und ihre verwendungen
AP2009005041A0 (en) Polynucleotides and polypeptides involved in gestational malaria, and biological applications
GB0808207D0 (en) Order force effects, states and reactions
GB0724909D0 (en) Improvements in catalysts
IL189812A0 (en) Eg8798 and eg9703 polynucleotides and uses thereof
GB0720675D0 (en) Oligonucleotides and uses thereof
GB0711792D0 (en) Order force effects, states and reactions
GB0708819D0 (en) Order force effects, states and reactions